2.7.7.7	A329A	not meaningfully associated with breast cancer risk; more likely to respond to Pt-based chemotherapy	761958	
2.7.7.7	A408S	A408S mutation results in a significant increase in both dNTP binding affinity and fidelity, kcat/Km for dATP is about 45% compared to the wild-type enzyme, D215A mutation results in inactivation of 3'-5'-exonuclease activity	721612	
2.7.7.7	A467T	naturally occuring mutation, the mutation is the most common POLG mutation and has been found to be associated with all of the disease symptoms analyzed. The A467T pol gamma possesses only 4% of the wild-type DNA polymerase activity and is compromised for its ability to interact with the p55 accessory subunit	723108	
2.7.7.7	A471V	moderate decrease in activity	761958	
2.7.7.7	A957S	naturally occuring mutation, involved in autosomal dominant progressive external ophthalmoplegia, the mutation is associated with motiif B in the active site	723108	
2.7.7.7	D10A	retains polymerase activity, reduced exonuclease activity, changes in dependency on metal activation of exonuclease activity	643653	
2.7.7.7	D111A	94% loss of DNA polymerase activity	726027	
2.7.7.7	D1122A	loss of polymerization activity	722619	
2.7.7.7	D1122E	mutant enzyme with reduced polymerization activity, polymerization activity is 15% compared to wild-type activity, 3'-5' exonuclease activity remains, the mutant has lower Mg2+ affinity than does the wild-type	722619	
2.7.7.7	D1124A	loss of polymerization activity	722619